Jaguar LAA Acquires Assets of the Laminar Program from Johnson & Johnson
Jaguar LAA, Inc., a privately held medical device company based in Santa Rosa, California, has acquired key assets related to the Laminar program for left atrial appendage (LAA) closure. The technology is designed for patients with non-valvular atrial fibrillation and uses a catheter-based approach involving rotational motion to close the LAA while minimizing device exposure within the heart. The acquisition includes both physical assets and team members who were instrumental in developing the program, now consolidated under Jaguar's newly formed independent company. The transaction was facilitated by Santé Ventures alongside management and other investors. Financial details of the deal have not been disclosed. Jaguar aims to build on existing clinical work and advance the Laminar program through further development and regulatory review. This move positions the company as a key player in developing innovative solutions for stroke prevention in patients with atrial fibrillation.
Tickers: $JNJ